Fidelity International
LSB

Fidelity International’s LakeShore Biopharma LSB Stock Holding History

Fidelity International’s Portfolio LSB Stock Details LSB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-61,548
Closed -$424K – 992
2024
Q3 		$424K Sell
61,548
-11,794
-16% -$61.1K ﹤0.01% 789
2024
Q2 		$475K Sell
73,342
-47,134
-39% -$385K ﹤0.01% 757
2024
Q1 		$843K Sell
120,476
-99,757
-45% -$508K ﹤0.01% 729
2023
Q4 		$1.18M Sell
220,233
-50,334
-19% -$290K ﹤0.01% 696
2023
Q3 		$2.16M Sell
270,567
-1,283
-0.5% -$14.8K ﹤0.01% 629
2023
Q2 		$3.75M Hold
271,850
– – ﹤0.01% 591
2023
Q1 		$4.35M Buy
+271,850
New +$13.8M 0.01% 581

Other funds holding LSB

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
SCM
Superstring Capital Management New York $158M AUM 418.32% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Fidelity International's LSB Position: Q4 2024 in Review

Fidelity International sold out of LakeShore Biopharma (LSB) in Q4 2024, closing a stake of 61,548 shares — an estimated $424K sold.

Fidelity International first reported a position in LSB in Q1 2023 and held it in 7 quarters. The position peaked at $4.35M in Q1 2023. 6 funds tracked by Wall St. Rank hold LSB as of Q4 2024.

  • Fidelity International reported no remaining LakeShore Biopharma position as of Q4 2024 after selling out during the quarter.
  • Fidelity International sold 61,548 LakeShore Biopharma shares in Q4 2024, an estimated $424K.
  • Fidelity International first reported a position in LakeShore Biopharma in Q1 2023 and held it in 7 quarters.
  • Fidelity International's LakeShore Biopharma position peaked at $4.35M in Q1 2023.
  • 6 funds tracked by Wall St. Rank held LakeShore Biopharma as of Q4 2024.

Based on Fidelity International's 13F filing for Q4 2024, filed 13 Feb 2025.